Hours

Minutes

Seconds

-40%

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

ABION Inc. is a Korea-based company principally engaged in the research, development and sales of pharmaceuticals. Along with its subsidiaries, the Company operates its business through four segments including product segment, contract research organization (CRO) service segment, research segment and other segment. The Product segment produces and sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment provides histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services. The Research segment is engaged in research and development of drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
16/06/26	1,268.00 ₩	+0.63%	623,705
15/06/26	1,260.00 ₩	+2.86%	897,278
12/06/26	1,225.00 ₩	-0.65%	1,310,176
11/06/26	1,233.00 ₩	-1.36%	1,304,518
10/06/26	1,250.00 ₩	-6.72%	1,455,131

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 16/06/2026			5-day change	1st Jan Change
1,268.00 ^KRW	+0.63%		+2.67%	-59.49%

04-07	ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs	CI
04/04/25	Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc	RE

Market Cap	114B 75.72M 65.25M 60.09M 56.42M 106M 7.16B 107M 710M 277M 3.51B 284M 278M 12.15B	P/E Ratio 2024	-4.02x	P/E Ratio 2025	-7.21x
Enterprise Value	85.91B 56.94M 49.07M 45.19M 42.43M 79.65M 5.38B 80.5M 534M 208M 2.64B 214M 209M 9.14B	EV / Sales 2024	282x	EV / Sales 2025	288x
Free-Float	67.22%	Yield 2024 *	-	Yield 2025	-

04-07	ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs	CI
04/04/25	Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc	RE
30/12/24	Nuon Co., Ltd. completed the acquisition of 4.06% stake in ABION Inc. from KPM TECH Co., Ltd..	CI
26/12/24	KPM TECH Co., Ltd. announced that it has received KRW 5.999999711 billion in funding from ABION Inc.	CI
23/12/24	Nuon Co., Ltd. agreed to acquire 4.06% stake in ABION Inc. from KPM TECH Co., Ltd. for KRW 8 billion.	CI
23/12/24	ABION Inc. announced that it has received KRW 8.0011152 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
18/12/24	KPM TECH Co., Ltd. announced that it expects to receive KRW 5.999999711 billion in funding from ABION Inc.	CI
05/12/24	ABION Inc. completed the acquisition of 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc..	CI
05/12/24	ABION Inc. announced that it has received KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
11/11/24	ABION Inc. announced that it expects to receive KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
11/11/24	ABION Inc. agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. for KRW 20.1 billion.	CI
28/10/24	ABION Inc. announced that it expects to receive KRW 9.999995616 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
28/12/23	Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.	CI

1 day	+0.63%
1 week	+2.67%
Current month	-32.66%
1 month	-37.54%
3 months	-59.10%
6 months	-56.87%
Current year	-59.49%

Abion Inc. Stock

Stocks

A203400

KR7203400007

Biotechnology & Medical Research

Valuation: Abion Inc.

Chart: Abion Inc.

Latest news : Abion Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Abion Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,169	1,371
1 month	1,066	2,400
Current year	1,066	4,335
1 year	1,066	7,277.78
3 years	1,066	7,277.78
5 years	1,066	14,694.44
10 years	1,066	14,694.44

Manager	Title	Age	Since
Young-Gi Shin CEO	Chief Executive Officer	55	01/08/2010
Seong-Yun Woo DFI	Director of Finance/CFO	45	28/03/2025
Gi-Ryong Jang COO	Chief Operating Officer	46	01/01/2026

Director	Title	Age	Since
Young-Gi Shin BRD	Director/Board Member	55	31/12/2014
Jin-Wook Yang BRD	Director/Board Member	56	25/03/2022
Geun-Chul Park BRD	Director/Board Member	70	-

Date	Insider	Type	Quantity	% Market Cap.
12-08	Sun-mi Chang	Buy	34	0.0001%
12-08	Yang-mi Lim	Free	92	0.0002%
12-08	Sun-mi Chang	Free	27	0.0001%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABION INC.	+0.63%	+2.67%	-50.60%	-70.44%	75.05M
ARGENX SE	-0.71%	-0.97%	+50.38%	+109.48%	54.92B
WUXI APPTEC CO., LTD.	-1.22%	+2.25%	+43.78%	+38.45%	44.31B
BIONTECH SE	-1.43%	+3.47%	-15.83%	-20.48%	22.96B
INSMED INCORPORATED	-1.99%	-3.55%	-5.97%	+377.60%	21.12B
WUXI BIOLOGICS (CAYMAN) INC.	-2.91%	-1.18%	+7.21%	-36.53%	16.31B
GENMAB A/S	-2.38%	-3.41%	+5.06%	-40.72%	15.19B
EXELIXIS, INC.	-1.70%	-1.68%	+24.79%	+172.92%	13.32B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.48%	+11.36%	+22.59%	-	12.48B
PHARMAESSENTIA CORPORATION	+4.10%	+7.02%	+104.41%	+226.33%	11.21B
Average	-0.61%	+2.54%	+18.58%	+84.07%	21.19B
Weighted average by Cap.	-0.99%	+2.01%	+29.22%	+94.49%

	2024	2025
Net sales	760M 503K 434K 400K 375K 704K 47.6M 712K 4.72M 1.84M 23.31M 1.89M 1.85M 80.78M	880M 583K 503K 463K 435K 816K 55.15M 825K 5.47M 2.13M 27.01M 2.19M 2.14M 93.59M
Net income	-43.38B -28.75M -24.78M -22.82M -21.42M -40.22M -2.72B -40.64M -270M -105M -1.33B -108M -106M -4.61B	-29.06B -19.26M -16.6M -15.29M -14.35M -26.95M -1.82B -27.23M -181M -70.37M -892M -72.29M -70.75M -3.09B
Net Debt	14.05B 9.31M 8.02M 7.39M 6.94M 13.02M 880M 13.16M 87.3M 34.01M 431M 34.94M 34.19M 1.49B	-28.33B -18.78M -16.18M -14.9M -13.99M -26.27M -1.78B -26.55M -176M -68.6M -869M -70.47M -68.98M -3.01B